TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07624214: A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-010391 Tablets in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 198 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07624214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07624214 Rescue Dossier →